QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.73B.
Overvalued
The company’s latest PE is -1.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.33M shares, decreasing 13.83% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 312.25K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.45.